Study Number:	I20263
Study Gender:	Both
PWG Approval Date:	See web page for date of PWG Approval
Version:	v1.7.0

F1 Male: Immunopath

	Treatment Groups (ppm)			
	0	**2500**	**5000**	**10000**
Disposition Summary				
Animals Initially In Study	**12**	**12**	**12**	**11**
Censored				
Early Deaths				
Survivors				
Scheduled Sacrifice, Terminal	**12**	**12**	**12**	**11**
Number Animals Examined Microscopically	**12**	**12**	**12**	**11**
ALIMENTARY SYSTEM				
No Tissues/Organs Examined				
CARDIOVASCULAR SYSTEM				
No Tissues/Organs Examined				
ENDOCRINE SYSTEM				
ADRENAL GLAND	(12)	(12)	(12)	(11)
CORTEX; VACUOLATION; DIFFUSE	1 (8%)	3 (25%)	1 (8%)	
GENERAL BODY SYSTEM				
No Tissues/Organs Examined				
HEMATOPOIETIC SYSTEM				
BONE MARROW	(12)	(12)	(12)	(11)
MYELOID CELL; NUMBER INCREASED				1 (9%)
HEPATOBILIARY SYSTEM				
LIVER	(12)	(12)	(12)	(11)
EOSINOPHILIC FOCUS				1 (9%)
EXTRAMEDULLARY HEMATOPOIESIS	3 (25%)	5 (42%)	9 (75%)	
SUBCAPSULAR; FIBROSIS; FOCAL			1 (8%)	
HEPATODIAPHRAGMATIC NODULE		2 (17%)	1 (8%)	
BILE DUCT; HYPERPLASIA		2 (17%)	9 (75%)	11 (100%)
INFILTRATION CELLULAR; MIXED	11 (92%)	8 (67%)	12 (100%)	10 (91%)

F1 Male: Immunopath

	Treatment Groups (ppm)			
	0	**2500**	**5000**	**10000**
IMMUNE SYSTEM				
BALT	(12)	(12)	(12)	(11)
LYMPH NODE	(0)	(1)	(0)	(0)
MESENTERIC, SINUS, PIGMENTED MACROPHAGE; NUMBER INCREASED		1 (100%)		
LYMPH NODE, MESENTERIC	(12)	(12)	(12)	(11)
SINUS; ERYTHROPHAGOCYTOSIS		1 (8%)		
SINUS ERYTHROCYTOSIS		1 (8%)		
LYMPH NODE, POPLITEAL	(12)	(11)	(12)	(11)
PIGMENT	7 (58%)	10 (91%)	6 (50%)	7 (64%)
SPLEEN	(12)	(12)	(12)	(11)
ACCESSORY SPLEEN			1 (8%)	
THYMUS	(12)	(12)	(12)	(11)
INTEGUMENTARY SYSTEM				
No Tissues/Organs Examined				
MUSCULOSKELETAL SYSTEM				
BONE	(12)	(12)	(12)	(11)
NERVOUS SYSTEM				
No Tissues/Organs Examined				
REPRODUCTIVE SYSTEM				
No Tissues/Organs Examined				
RESPIRATORY SYSTEM				
LUNG	(12)	(12)	(12)	(11)
ALVEOLUS; INFILTRATION CELLULAR; HISTIOCYTE	7 (58%)	5 (42%)	7 (58%)	6 (55%)
SPECIAL SENSES SYSTEM				
No Tissues/Organs Examined				

F1 Male: Immunopath

	Treatment Groups (ppm)			
	0	**2500**	**5000**	**10000**
URINARY SYSTEM				
KIDNEY	(12)	(12)	(12)	(11)
RENAL TUBULE; CAST; HYALINE	6 (50%)	6 (50%)	1 (8%)	3 (27%)
CHRONIC PROGRESSIVE NEPHROPATHY	5 (42%)	2 (17%)	5 (42%)	3 (27%)
PELVIS; DILATION				2 (18%)
FIBROSIS				1 (9%)
UROTHELIUM; HYPERPLASIA				1 (9%)
INTERSTITIUM; INFILTRATION CELLULAR; LYMPHOHISTIOCYTIC			1 (8%)	1 (9%)
PELVIS; INFLAMMATION; CHRONIC-ACTIVE				1 (9%)
URINARY BLADDER	(0)	(0)	(0)	(1)
CALCULUS				1 (100%)
DILATION				1 (100%)
UROTHELIUM; HYPERPLASIA				1 (100%)
MUCOSA; INFLAMMATION; CHRONIC-ACTIVE				1 (100%)

F1 Female: Immunopath

	Treatment Groups (ppm)			
	0	**2500**	**5000**	**10000**
Disposition Summary				
Animals Initially In Study	**12**	**12**	**12**	**11**
Censored		**1**		
Early Deaths				
Survivors				
Scheduled Sacrifice, Terminal	**12**	**11**	**12**	**11**
Number Animals Examined Microscopically	**12**	**11**	**12**	**11**
ALIMENTARY SYSTEM				
No Tissues/Organs Examined				
CARDIOVASCULAR SYSTEM				
No Tissues/Organs Examined				
ENDOCRINE SYSTEM				
ADRENAL GLAND	(12)	(11)	(12)	(11)
ACCESSORY ADRENOCORTICAL NODULE	2 (17%)	1 (9%)	1 (8%)	1 (9%)
CORTEX; HYPERTROPHY; FOCAL	2 (17%)			
CORTEX; VACUOLATION; DIFFUSE				1 (9%)
GENERAL BODY SYSTEM				
No Tissues/Organs Examined				
HEMATOPOIETIC SYSTEM				
BONE MARROW	(12)	(11)	(12)	(11)
HEPATOBILIARY SYSTEM				
LIVER	(12)	(11)	(12)	(11)
EOSINOPHILIC FOCUS		1 (9%)		
EXTRAMEDULLARY HEMATOPOIESIS	3 (25%)		5 (42%)	6 (55%)
HEPATODIAPHRAGMATIC NODULE	1 (8%)			
BILE DUCT; HYPERPLASIA	1 (8%)		4 (33%)	10 (91%)
INFILTRATION CELLULAR; MIXED	11 (92%)	11 (100%)	11 (92%)	9 (82%)

F1 Female: Immunopath

	Treatment Groups (ppm)			
	0	**2500**	**5000**	**10000**
IMMUNE SYSTEM				
BALT	(12)	(11)	(11)	(11)
LYMPH NODE, MESENTERIC	(12)	(11)	(12)	(11)
SINUS; ERYTHROPHAGOCYTOSIS	1 (8%)			
SINUS, MACROPHAGE; PIGMENT	1 (8%)			
SINUS ERYTHROCYTOSIS	1 (8%)			
LYMPH NODE, POPLITEAL	(11)	(11)	(12)	(10)
PIGMENT	8 (73%)	6 (55%)	7 (58%)	4 (40%)
SPLEEN	(12)	(11)	(12)	(11)
ACCESSORY SPLEEN			1 (8%)	1 (9%)
THYMUS	(12)	(11)	(12)	(11)
INTEGUMENTARY SYSTEM				
No Tissues/Organs Examined				
MUSCULOSKELETAL SYSTEM				
BONE	(12)	(11)	(11)	(11)
NERVOUS SYSTEM				
No Tissues/Organs Examined				
REPRODUCTIVE SYSTEM				
No Tissues/Organs Examined				
RESPIRATORY SYSTEM				
LUNG	(12)	(11)	(12)	(11)
ALVEOLUS; INFILTRATION CELLULAR; HISTIOCYTE	9 (75%)	8 (73%)	10 (83%)	9 (82%)
INTERSTITIUM; INFILTRATION CELLULAR; MIXED		1 (9%)		
SPECIAL SENSES SYSTEM				
No Tissues/Organs Examined				

F1 Female: Immunopath

	Treatment Groups (ppm)			
	0	**2500**	**5000**	**10000**
URINARY SYSTEM				
KIDNEY	(12)	(11)	(12)	(11)
RENAL TUBULE; CAST; HYALINE	2 (17%)	1 (9%)		
CHRONIC PROGRESSIVE NEPHROPATHY	3 (25%)	4 (36%)	2 (17%)	1 (9%)
INTERSTITIUM; INFILTRATION CELLULAR; LYMPHOHISTIOCYTIC	1 (8%)	3 (27%)	1 (8%)	1 (9%)
INFILTRATION CELLULAR; LYMPHOHISTIOCYTIC			1 (8%)	

LEGEND

For this study, "Censored" refers to one female in the 2500 ppm group that was euthanized because it escaped from the cage.
Number of animals examined given for each tissue.
In the rows with the tissue names, the number of animals examined for each tissue is shown in parentheses.

** END OF REPORT **